Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer

BACKGROUND: In this open‐label, Phase 1 study, we explore the safety and efficacy of E7389‐LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors. METHODS: This open‐label, Phase 1 study enrolled Japanese adult patients to receive E7389‐LF for the treatment of advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Udagawa, Hibiki, Takahashi, Shunji, Hirao, Motohiro, Tahara, Makoto, Iwasa, Satoru, Sato, Yasuyoshi, Hamakawa, Takuya, Shitara, Kohei, Horinouchi, Hidehito, Chin, Keisho, Masuda, Norikazu, Suzuki, Takuya, Okumura, Shiori, Takase, Takao, Nagai, Reiko, Yonemori, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883537/
https://www.ncbi.nlm.nih.gov/pubmed/35864593
http://dx.doi.org/10.1002/cam4.4996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883537/
https://www.ncbi.nlm.nih.gov/pubmed/35864593
http://dx.doi.org/10.1002/cam4.4996

Ejemplares similares